JP EQUITY · SINGLE-STOCK DEEP DIVE · ENEOSホールディングス

ENEOS(ENEOSホールディングス) — 정유 — 일본 최대 · IFRSENEOS Holdings (ENEOSホールディングス) — Refining — Japan's largest · IFRSENEOSホールディングス — 石油精製 — 国内最大 · IFRS

EDINET 有価証券報告書 FY2017~FY2025 를 이어 붙인 공통 재무 점검. 매출 103,011 → 117,655억엔, 영업이익률 4.7% → 4.0%, ROIC 7.8% → 6.4%. 정유사는 이익의 큰 몫이 재고평가(유가 방향)에서 온다 — 그 몫을 먼저 걷어 내고 본다(②). 손익 엔진·현금·운전자본·자본 배분·장부 점검·밸류에이션, 그리고 이 주가가 이익(P/E)을 따라가는지 장부(P/B)에 묶였는지를 같은 틀로 잰다. 방향은 단정하지 않는다.A common financial check built by linking EDINET annual securities reports for FY2017~FY2025. Revenue 103,011 → 117,655 JPY 100mn, operating margin 4.7% → 4.0%, ROIC 7.8% → 6.4%. For refiners a large share of profit comes from inventory valuation (the direction of oil prices) — that share is stripped out first (②). The profit engine, cash, working capital, capital allocation, accounting checks and valuation — and whether this share price tracks earnings (P/E) or is anchored to book value (P/B) — are measured with the same frame. No view on direction is taken.EDINETの有価証券報告書FY2017~FY2025をつなぎ合わせた共通の財務点検。売上高103,011 → 117,655億円、 営業利益率4.7% → 4.0%、ROIC 7.8% → 6.4%。 石油元売りは利益の大きな部分が在庫評価(原油価格の方向)から来る — その分をまず取り除いて見る(②)。 損益エンジン・現金・運転資本・資本配分・帳簿点検・バリュエーション、そしてこの株価が利益(P/E)に連動するのか簿価(P/B)に縛られているのかを同じ枠組みで測る。方向は断定しない。

FY = 결산월이 1~3월이면 그 전해, 4~12월이면 그해(2026년 3월 결산 = FY2025 · 2025년 8월 결산 = FY2025). 회계기준 IFRS — IFRS 엔 経常利益·特別損益 구분이 없어 그 칸은 비운다. 기말 주가·시가총액·P/B 는 그해 有報의 EPS × PER 로 역산한 가공값(적자 해는 PER 미기재로 빈칸). 분기보고서는 2024년 4월 폐지 — 그 뒤는 반기뿐이다(마지막 반기 2025 H2 · 2026-03-31).FY = 결산월이 1~3월이면 그 전해, 4~12월이면 그해(2026년 3월 결산 = FY2025 · 2025년 8월 결산 = FY2025). Accounting standard: IFRS — IFRS has no ordinary profit / extraordinary items split, so those cells are left blank. Year-end share prices, market cap and P/B are derived values back-calculated as EPS × P/E from that year’s annual securities report (loss years are blank because P/E is not reported). Quarterly securities reports were abolished in April 2024 — after that there are only half-year figures (last half 2025 H2 · 2026-03-31).FY = 결산월이 1~3월이면 그 전해, 4~12월이면 그해(2026년 3월 결산 = FY2025 · 2025년 8월 결산 = FY2025). 会計基準IFRS — IFRSには経常利益・特別損益の区分がないため、その欄は空欄にする。 期末株価・時価総額・P/Bはその年の有報のEPS × PERから逆算した加工値(赤字の年はPER記載なしのため空欄)。 四半期報告書は2024年4月に廃止 — それ以降は半期のみ(直近の半期2025 H2 · 2026-03-31)。
매출 FY2025Revenue FY2025売上高 FY2025117,655억엔117,655 JPY 100mn117,655億円FY2017 103,011억엔FY2017 103,011 JPY 100mnFY2017 103,011億円
영업이익률Operating margin営業利益率4.0%FY2017 4.7%
ROIC(영업 투하자본)ROIC (operating invested capital)ROIC(営業投下資本)6.4%고점 FY2021 11.8%Peak FY2021 11.8%ピーク FY2021 11.8%
안전마진Margin of safety安全余裕率22.6%영업 레버리지 3.33배Operating leverage 3.33x営業レバレッジ3.33倍
누적 FCFCumulative FCF累計FCF21,143억엔21,143 JPY 100mn21,143億円FY2017~FY2025
P/B (가공)P/B (derived)P/B(加工値)1.13배1.13x1.13倍범위 0.49~1.13Range 0.49~1.13範囲0.49~1.13
P/E14.7배14.7x14.7倍배당수익률 2.41%Dividend yield 2.41%配当利回り2.41%
P/E 냐 P/B 냐P/E or P/BP/EかP/Bかβ 0.06장부에 묶임Anchored to book簿価に縛られる

① 손익 패널Income statement panel損益パネル — FY2017~FY2025

억엔 · 비율 = 매출 대비 % · FY = 결산월이 1~3월이면 그 전해, 4~12월이면 그해(2026년 3월 결산 = FY2025 · 2025년 8월 결산 = FY2025).JPY 100mn · ratios = % of revenue · FY = 결산월이 1~3월이면 그 전해, 4~12월이면 그해(2026년 3월 결산 = FY2025 · 2025년 8월 결산 = FY2025).億円 · 比率 = 売上高比% · FY = 결산월이 1~3월이면 그 전해, 4~12월이면 그해(2026년 3월 결산 = FY2025 · 2025년 8월 결산 = FY2025). · Data as of 2026-03-31 · Created 2026-11-01
FY매출Revenue売上高매출총이익률Gross margin売上総利益率판관비율SG&A ratio販管費率연구개발/매출R&D/revenue研究開発費/売上高영업이익Operating profit営業利益영업이익률Operating margin営業利益率순이익Net profit純利益ROE
2017103,01112.5%7.6% —%4,8754.7% 3,619 14.2%
2018111,29611.0%7.3% 0.2%5,3714.8% 3,223 12.3%
2019100,1187.6%8.3% 0.2%-1,131-1.1% -1,879 -7.5%
202076,58014.1%10.5% 0.3%2,5423.3% 1,140 4.9%
2021109,21814.5%8.0% 0.2%7,8597.2% 5,371 20.7%
2022150,1668.1%6.4% 0.2%2,8131.9% 1,438 5.0%
2023138,5679.7%6.9% 0.2%4,6493.4% 2,881 9.5%
2024123,2259.0%7.0% 0.1%1,0610.9% 2,261 7.1%
2025117,65510.4%7.4% 0.1%4,6664.0% 2,587 8.0%
반기Half半期매출Revenue売上高매출총이익률Gross margin売上総利益率판관비SG&A販管費영업이익Operating profit営業利益영업이익률Operating margin営業利益率경상이익Ordinary profit経常利益순이익Net profit純利益
2024 H163,484 — —1,460 2.3% —682
2024 H259,741 — —-399 -0.7% —1,579
2025 H156,919 — —1,667 2.9% —648
2025 H260,735 — —2,999 4.9% —1,940
매출은 FY2017 103,011억엔에서 FY2025 117,655억엔(연 1.7%), 영업이익률은 4.7% → 4.0%. IFRS — 経常利益·特別損益 구분이 없어 그 열은 뺐다. 2024-04 四半期報告書 폐지로 2024년 하반기부터는 반기만 있다 — 최근 반기 2025 H2 영업이익 2,999억엔(전년 같은 반기 -399억엔).Revenue went from 103,011 JPY 100mn in FY2017 to 117,655 JPY 100mn in FY2025 (1.7% a year); operating margin 4.7% → 4.0%. IFRS — there is no ordinary profit / extraordinary items split, so those columns are dropped. With quarterly securities reports abolished in April 2024, only half-year figures exist from the second half of 2024 — latest half 2025 H2: operating profit 2,999 JPY 100mn (same half a year earlier -399 JPY 100mn).売上高はFY2017の103,011億円からFY2025の117,655億円(年率1.7%)、営業利益率は4.7% → 4.0%。 IFRS — 経常利益・特別損益の区分がないため、その列は除いた。2024年4月の四半期報告書廃止により、2024年下期からは半期のみ — 直近の半期2025 H2の営業利益2,999億円(前年同半期-399億円)。

② 재고평가 효과 — 이익 중 유가가 만든 몫Inventory valuation effect — the share of profit made by oil prices在庫評価影響 — 利益のうち原油価格がもたらした分

억엔JPY 100mn億円 · Data as of 2026-03-31 · Created 2026-11-01
FY기준 이익Profit measure基準利益보고 이익Reported profit報告利益재고평가 효과Inventory valuation effect在庫評価影響효과 제외 이익Profit ex. effect影響除く利益|효과| ÷ 보고 이익|Effect| ÷ reported profit|影響| ÷ 報告利益
2016営業利益Operating profit営業利益2,711 1,3001,411 48%
2017営業利益Operating profit営業利益4,875 1,1493,726 24%
2018営業利益Operating profit営業利益5,371 2145,157 4%
2019営業利益Operating profit営業利益-1,131 -2,098967 186%
2020営業利益Operating profit営業利益2,542 3872,155 15%
2021営業利益Operating profit営業利益7,859 3,7034,156 47%
2022営業利益Operating profit営業利益2,813 3482,465 12%
2023営業利益Operating profit営業利益4,649 7173,932 15%
2024営業利益Operating profit営業利益1,061 -5761,637 54%
2025営業利益Operating profit営業利益4,666 -784,744 2%
재고평가 효과 누계 5,066억엔 · 보고 이익 대비 |효과| 중앙값 24% · 가장 큰 해 FY2021 3,703억엔. 재고평가 효과 + = 유가 상승기 원가 押し下げ(이익 증가), − = 하락기 押し上げ. 기준 이익은 회사가 MD&A·결산 설명에서 쓴 것 그대로. 손익 엔진·ROIC 는 보고 이익 그대로라 이 효과가 섞여 있다.Cumulative inventory valuation effect 5,066 JPY 100mn · median |effect| relative to reported profit 24% · largest year FY2021 3,703 JPY 100mn. 재고평가 효과 + = 유가 상승기 원가 押し下げ(이익 증가), − = 하락기 押し上げ. 기준 이익은 회사가 MD&A·결산 설명에서 쓴 것 그대로. The profit engine and ROIC use reported profit as is, so this effect is mixed in.在庫評価影響の累計5,066億円 · 報告利益に対する|影響|の中央値24% · 最大の年FY2021 3,703億円。재고평가 효과 + = 유가 상승기 원가 押し下げ(이익 증가), − = 하락기 押し上げ. 기준 이익은 회사가 MD&A·결산 설명에서 쓴 것 그대로. 損益エンジン・ROICは報告利益のままのため、この影響が混じっている。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 회사가 MD&A·결산 설명에 밝힌 재고평가 영향을 옮겼다 — 회사마다 기준 이익(営業利益·セグメント利益·経常利益)이 다르고, 영향을 밝히지 않은 해는 빠진다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Inventory valuation effects as disclosed by the company in its MD&A and results briefings — the profit measure differs by company (operating profit, segment profit, ordinary profit), and years in which the effect was not disclosed are omitted.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 会社がMD&A・決算説明で開示した在庫評価影響を転記した — 基準とする利益(営業利益・セグメント利益・経常利益)は会社ごとに異なり、影響を開示していない年は含まない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

③ 비용 구조 — 매출 1엔이 어디로 가나Cost structure — where each yen of revenue goesコスト構造 — 売上1円はどこへ行くか

매출 대비 %% of revenue売上高比% · Data as of 2026-03-31 · Created 2026-11-01
매출원가율 FY2017 87.5% → FY2025 89.6% · 판관비율 7.6% → 7.4% · 연구개발/매출 —% → 0.1% · 감가상각/매출 2.6% → 2.8%. 판관비는 손익계산서 합계(판매비·일반관리비 구분 없음), 연구개발비는 주석의 총액(판관비 안 포함분), 감가상각은 현금흐름표 합계라 다른 선과 겹친다 — 더하면 안 된다.Cost-of-sales ratio FY2017 87.5% → FY2025 89.6% · SG&A ratio 7.6% → 7.4% · R&D/revenue —% → 0.1% · depreciation/revenue 2.6% → 2.8%. SG&A is the income-statement total (no split between selling and G&A expenses); R&D is the total from the notes (including the part within SG&A) and depreciation is the cash-flow-statement total, so they overlap with the other lines — do not add them up.売上原価率FY2017 87.5% → FY2025 89.6% · 販管費率7.6% → 7.4% · 研究開発費/売上高—% → 0.1% · 減価償却費/売上高2.6% → 2.8%。 販管費は損益計算書の合計(販売費・一般管理費の区分なし)、研究開発費は注記の総額(販管費に含まれる分を含む)、減価償却費はキャッシュ・フロー計算書の合計のため、他の線と重複する — 足し合わせてはならない。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 판관비 구분·연구개발비·감가상각은 원문 계정 그대로라 서로 겹친다(연구개발비는 판관비·제조원가 안에, 감가상각은 현금흐름표 합계) — 더하면 안 된다. 세로축은 로그 눈금.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: The SG&A breakdown, R&D and depreciation follow the original accounts and overlap (R&D sits inside SG&A and manufacturing cost; depreciation is the cash-flow-statement total) — do not add them up. The vertical axis is on a log scale.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 販管費の内訳・研究開発費・減価償却費は原文の勘定科目のままで互いに重複する(研究開発費は販管費・製造原価の中、減価償却費はキャッシュ・フロー計算書の合計)— 足し合わせてはならない。縦軸は対数目盛。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

④ 손익 엔진 — 고정비가 얼마나 무거워졌나Profit engine — how much heavier fixed costs have become損益エンジン — 固定費はどれだけ重くなったか

억엔 · % · 계정 분류(勘定科目法)JPY 100mn · % · account-classification method億円 · % · 勘定科目法 · Data as of 2026-03-31 · Created 2026-11-01
안전마진 — 매출이 몇 % 빠지면 영업적자인가Margin of safety — how far revenue can fall (%) before an operating loss安全余裕率 — 売上が何%減ると営業赤字か
FY201732.3%
FY202522.6%
손익분기 매출 69,696 → 91,051억엔Break-even revenue 69,696 → 91,051 JPY 100mn損益分岐点売上高69,696 → 91,051億円
고정비(판관비 + 감가상각)Fixed costs (SG&A + depreciation)固定費(販管費 + 減価償却費)
FY201710,518억엔10,518 JPY 100mn10,518億円
FY202512,015억엔12,015 JPY 100mn12,015億円
공헌이익률 15.1% → 13.2%Contribution margin 15.1% → 13.2%限界利益率15.1% → 13.2%
영업 레버리지 — 매출 1% 변화 → 영업이익 몇 %Operating leverage — % change in operating profit per 1% change in revenue営業レバレッジ — 売上1%の変化 → 営業利益は何%
FY20173.19배3.19x3.19倍
FY20253.33배3.33x3.33倍
공헌이익 ÷ 영업이익Contribution ÷ operating profit限界利益 ÷ 営業利益
변동비율 여유 — 원가율이 몇 %p 오르면 적자인가Variable-cost headroom — how many pp the cost ratio can rise before a loss変動費率の余裕 — 原価率が何%pt上がると赤字か
FY20253.0%p3.0pp3.0%pt
= 영업이익률. 원료가가 판가보다 이만큼 더 오르면 고정비를 못 덮는다.= operating margin. If raw-material prices rise this much more than selling prices, fixed costs are no longer covered.= 営業利益率。原料価格が販売価格よりこれだけ多く上がると、固定費を賄えない。
FY매출Revenue売上高변동비Variable costs変動費고정비Fixed costs固定費공헌이익률Contribution margin限界利益率손익분기 매출Break-even revenue損益分岐点売上高안전마진Margin of safety安全余裕率영업 레버리지Operating leverage営業レバレッジ
2017103,01187,46610,518 15.1%69,69632.3%3.19
2018111,29696,61410,646 13.2%80,69727.5%2.73
2019100,11889,19111,559 10.9%105,904-5.8%-9.66
202076,58062,47411,297 18.4%61,32719.9%5.55
2021109,21890,07412,035 17.5%68,66537.1%2.44
2022150,166134,52513,067 10.4%125,46216.4%5.56
2023138,567121,81312,864 12.1%106,39823.2%3.60
2024123,225108,53812,254 11.9%102,81416.6%13.84
2025117,655102,12912,015 13.2%91,05122.6%3.33
회귀로는 못 잰다Not measurable by regression回帰では測れない 분기 비용(매출 − 영업이익)을 매출에 회귀하면 기울기 0.98(±0.03, R² 0.97, 2016Q1~2023Q4 32분기) · 절편(분기 고정비) -364억엔. 비용이 매출과 거의 1:1 로 움직여(판가가 원료에 연동) 고정비가 통계적으로 잡히지 않는다 — 그래서 계정 분류로 나눴다.Regressing quarterly costs (revenue − operating profit) on revenue gives a slope of 0.98 (±0.03, R² 0.97, 2016Q1~2023Q4, 32 quarters) · intercept (quarterly fixed costs) -364 JPY 100mn. Costs move almost 1:1 with revenue (selling prices are linked to raw materials), so fixed costs cannot be identified statistically — hence the split by account.四半期コスト(売上高 − 営業利益)を売上高に回帰すると傾き0.98(±0.03、R² 0.97、2016Q1~2023Q4、32四半期)· 切片(四半期の固定費)-364億円。 コストが売上高とほぼ1:1で動く(販売価格が原料に連動)ため、固定費が統計的に捉えられない — そこで勘定科目で分けた。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 고정비·변동비는 계정으로 나눈 근사이지 회사가 공시한 원가 구조가 아니다 — 매출원가 안 인건비는 변동으로, 판관비 안 운임은 고정으로 들어간다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Fixed and variable costs are an approximation split by account, not a cost structure disclosed by the company — labour costs within cost of sales count as variable and freight within SG&A as fixed.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 固定費・変動費は勘定科目で分けた近似であり、会社が開示した原価構造ではない — 売上原価中の人件費は変動費に、販管費中の運賃は固定費に入る。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑤ 발생액 — 순이익 vs 영업현금흐름Accruals — net profit vs operating cash flow発生高 — 純利益 vs 営業キャッシュ・フロー

억엔JPY 100mn億円 · Data as of 2026-03-31 · Created 2026-11-01
발생액/총자산 3년 평균Accruals/total assets, 3-year average発生高/総資産 3年平均-5.0%
순이익 > 영업현금흐름인 해Years with net profit > operating cash flow純利益 > 営業キャッシュ・フローの年2 / 9년2 / 9 years2 / 9年
누적 영업현금흐름Cumulative operating cash flow累計営業キャッシュ・フロー45,475억엔45,475 JPY 100mn45,475億円
누적 순이익Cumulative net profit累計純利益20,641억엔20,641 JPY 100mn20,641億円
발생액 = 순이익 − 영업현금흐름. 음수면 현금이 이익보다 많이 들어왔다(감가상각이 큰 장치산업의 정상 모습). 크게 양수로 돌면 이익의 질을 의심한다.Accruals = net profit − operating cash flow. A negative value means more cash came in than profit (normal for capital-intensive industries with heavy depreciation). A large swing to positive casts doubt on earnings quality.発生高 = 純利益 − 営業キャッシュ・フロー。マイナスなら利益より多くの現金が入った(減価償却の大きい装置産業では正常な姿)。大きくプラスに転じたら利益の質を疑う。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 연결 연간 값. 영업현금흐름엔 운전자본 변동이 들어 있어 원료 시차가 큰 해에 크게 흔들린다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Consolidated annual figures. Operating cash flow includes working-capital changes, so it swings widely in years with large raw-material time lags.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 連結の年次値。営業キャッシュ・フローには運転資本の増減が含まれるため、原料のタイムラグが大きい年は大きく振れる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑥ CAPEX · FCF — 번 돈과 넣은 돈Capex · FCF — money earned and money investedCAPEX · FCF — 稼いだお金と投じたお金

억엔JPY 100mn億円 · Data as of 2026-03-31 · Created 2026-11-01
누적 설비투자 ÷ 누적 감가상각Cumulative capex ÷ cumulative depreciation累計設備投資 ÷ 累計減価償却費0.84배0.84x0.84倍
최근 3년 설비투자 ÷ 감가상각Capex ÷ depreciation, last 3 years直近3年の設備投資 ÷ 減価償却費0.86배0.86x0.86倍
누적 FCFCumulative FCF累計FCF21,143억엔21,143 JPY 100mn21,143億円
FCF 적자 연도Years with negative FCFFCFマイナスの年2021 · 2022
FCF 수익률 FY2025FCF yield FY2025FCF利回り FY20259.6%
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 설비투자는 유·무형자산 취득 현금만 — 리스로 들인 자산과 기업 인수는 빠진다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Capex covers only cash paid to acquire property, plant and equipment and intangible assets — leased assets and acquisitions are excluded.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 設備投資は有形・無形固定資産の取得による支出のみ — リースで取得した資産と企業買収は含まない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑦ 운전자본 — 매출채권 · 재고 · 매입채무 회전Working capital — receivables · inventory · payables turnover運転資本 — 売上債権・棚卸資産・仕入債務の回転

일 · 기말 잔액 기준Days · year-end balances日 · 期末残高ベース · Data as of 2026-03-31 · Created 2026-11-01
현금 전환 주기(CCC = DSO + DIO − DPO)는 FY2017 36일 → FY2025 44일 (매출채권 51 → 45일 · 재고 62 → 54일 · 매입채무 77 → 54일). 늘어난 8일을 FY2025 매출로 환산하면 약 2,643억엔이 운전자본에 더 묶여 있다. 매출채권은 전자기록채권 포함. 재고는 매출원가 기준.The cash conversion cycle (CCC = DSO + DIO − DPO) went from 36 days in FY2017 to 44 days in FY2025 (receivables 51 → 45 days · inventory 62 → 54 days · payables 77 → 54 days). Converting the 8 additional days at FY2025 revenue, about 2,643 JPY 100mn more is tied up in working capital. Receivables include electronically recorded monetary claims. Inventory is measured against cost of sales.キャッシュ・コンバージョン・サイクル(CCC = DSO + DIO − DPO)はFY2017の36日 → FY2025の44日 (売上債権51 → 45日 · 棚卸資産62 → 54日 · 仕入債務77 → 54日)。 増えた8日をFY2025の売上高で換算すると、約2,643億円が運転資本に余分に拘束されている。 売上債権は電子記録債権を含む。棚卸資産は売上原価ベース。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 기말 잔액 기준이라 결산일 계절성이 섞인다. 매출채권은 전자기록채권을 포함(공시된 해)하고, 재고·매입채무는 매출원가 기준.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Based on year-end balances, so balance-sheet-date seasonality is mixed in. Receivables include electronically recorded monetary claims (in years they are disclosed); inventories and payables are measured against cost of sales.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 期末残高ベースのため決算日の季節性が混じる。売上債権は電子記録債権を含み(開示された年)、棚卸資産・仕入債務は売上原価ベース。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑧ ROIC · ROE · ROA — 자본에서 얼마를 버나ROIC · ROE · ROA — how much is earned on capitalROIC・ROE・ROA — 資本からどれだけ稼ぐか

% · Data as of 2026-03-31 · Created 2026-11-01
ROIC(세후 영업이익 ÷ 영업 투하자본)는 FY2017 7.8% · 고점 FY2021 11.8% · FY2025 6.4%. 영업 투하자본 = 자기자본 + 이자부채 − 현금·단기유가증권 − 투자유가증권(정책보유주식 포함) — 본업에 묶인 돈만 남긴다. ROE·ROA 는 기초·기말 평균 분모.ROIC (after-tax operating profit ÷ operating invested capital) was 7.8% in FY2017 · peak FY2021 11.8% · FY2025 6.4%. Operating invested capital = equity + interest-bearing debt − cash and short-term securities − investment securities (including cross-shareholdings) — leaving only the money tied up in the core business. ROE and ROA use the average of opening and closing balances as the denominator.ROIC(税引後営業利益 ÷ 営業投下資本)はFY2017 7.8% · ピークFY2021 11.8% · FY2025 6.4%。 営業投下資本 = 自己資本 + 有利子負債 − 現金・短期有価証券 − 投資有価証券(政策保有株式を含む)— 本業に拘束されたお金だけを残す。ROE・ROAは期首・期末の平均を分母とする。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 영업 투하자본에서 투자유가증권(정책보유 포함)을 뺐다 · 세율은 그해 실효세율 · 기초·기말 평균 분모라 첫 해는 기말만.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Investment securities (including cross-shareholdings) are excluded from operating invested capital · the tax rate is that year's effective rate · denominators average opening and closing balances, so the first year uses the closing balance only.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 営業投下資本から投資有価証券(政策保有株式を含む)を除いた · 税率はその年の実効税率 · 分母は期首・期末の平均のため、初年度は期末のみ。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑨ 자본 배분 — FY2017~FY2025 누적, 돈은 어디로 갔나Capital allocation — cumulative FY2017~FY2025: where did the money go資本配分 — FY2017~FY2025累計、お金はどこへ行ったか

억엔 · 현금흐름표 누계JPY 100mn · cumulative cash-flow statement億円 · キャッシュ・フロー計算書の累計 · Data as of 2026-03-31 · Created 2026-11-01
영업현금흐름Operating cash flow営業キャッシュ・フロー45,475억엔45,475 JPY 100mn45,475億円
설비투자Capex設備投資24,331억엔24,331 JPY 100mn24,331億円
주주환원(배당 + 자사주)Shareholder returns (dividends + buybacks)株主還元(配当 + 自社株買い)10,826억엔10,826 JPY 100mn10,826億円
투자주식 매각 대금Proceeds from selling investment securities投資有価証券の売却収入2,972억엔2,972 JPY 100mn2,972億円
순현금 변화(기말 − 기초)Change in net cash (closing − opening)ネットキャッシュの増減(期末 − 期首)741억엔741 JPY 100mn741億円
FCF 21,143억엔 vs 주주환원 10,826억엔 — 환원은 FCF 안에서 했다. 누적은 첫 해 포함. 순현금 변화 = 마지막 해 − 첫 해 기말.FCF 21,143 JPY 100mn vs shareholder returns 10,826 JPY 100mn — returns were made within FCF. 누적은 첫 해 포함. 순현금 변화 = 마지막 해 − 첫 해 기말.FCF 21,143億円 vs 株主還元10,826億円 — 還元はFCFの範囲内で行った。 누적은 첫 해 포함. 순현금 변화 = 마지막 해 − 첫 해 기말.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 현금흐름표 누계 — 연결 범위 변경·환율 효과·기타 재무 항목은 따로 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Cumulative cash-flow-statement figures — changes in the scope of consolidation, FX effects and other financing items are not shown separately.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: キャッシュ・フロー計算書の累計 — 連結範囲の変更・為替の影響・その他の財務項目は個別に載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑩ 장부 점검 게이지 — 4개 플래그Accounting check gauges — 4 flags帳簿点検ゲージ — 4個のフラグ

빨강 0 · 주황 1 · 최근 연도 기준Red 0 · amber 1 · latest year赤0 · 橙1 · 直近年度ベース · Data as of 2026-03-31 · Created 2026-11-01
이익−현금 괴리(발생액/총자산, 3년 평균)Profit–cash gap (accruals/total assets, 3-year average)利益と現金の乖離(発生高/総資産、3年平均)
-5.0%-5.0%-5.0% · 기준 5%· threshold 5%· 基準5%
순이익이 영업현금흐름보다 크게 앞서면 이익의 질을 의심한다(Sloan).순이익이 영업현금흐름보다 크게 앞서면 이익의 질을 의심한다(Sloan).순이익이 영업현금흐름보다 크게 앞서면 이익의 질을 의심한다(Sloan).
매출채권 증가 − 매출 증가(최근 연도)Receivables growth − revenue growth (latest year)売上債権の増加 − 売上高の増加(直近年度)
6.6%6.6%6.6% · 기준 10%· threshold 10%· 基準10%
채권이 매출보다 빨리 늘면 밀어내기·회수 지연 신호.채권이 매출보다 빨리 늘면 밀어내기·회수 지연 신호.채권이 매출보다 빨리 늘면 밀어내기·회수 지연 신호.
재고 증가 − 매출 증가(최근 연도)Inventory growth − revenue growth (latest year)棚卸資産の増加 − 売上高の増加(直近年度)
2.5%2.5%2.5% · 기준 10%· threshold 10%· 基準10%
재고가 매출보다 빨리 늘면 수요 둔화를 재고로 받고 있을 수 있다(원가 이연).재고가 매출보다 빨리 늘면 수요 둔화를 재고로 받고 있을 수 있다(원가 이연).재고가 매출보다 빨리 늘면 수요 둔화를 재고로 받고 있을 수 있다(원가 이연).
설비투자 ÷ 감가상각(3년) vs 매출 연성장Capex ÷ depreciation (3 years) vs annual revenue growth設備投資 ÷ 減価償却費(3年)vs 売上高の年成長率
0.86배0.86x0.86倍 · 기준 2.0배· threshold 2.0x· 基準2.0倍
상각의 2배 넘게 투자하는데 매출 3년 연성장이 3% 미만이면 투자 회수가 의문. 매출 3년 연성장 -7.8%.상각의 2배 넘게 투자하는데 매출 3년 연성장이 3% 미만이면 투자 회수가 의문. 매출 3년 연성장 -7.8%.상각의 2배 넘게 투자하는데 매출 3년 연성장이 3% 미만이면 투자 회수가 의문. 매출 3년 연성장 -7.8%.

⑪ 밸류에이션 — P/B · P/E · EV/EBITDAValuation — P/B · P/E · EV/EBITDAバリュエーション — P/B・P/E・EV/EBITDA

배 · 기말 주가는 가공값x · year-end prices are derived values倍 · 期末株価は加工値 · Data as of 2026-03-31 · Created 2026-11-01
FY시가총액(억엔)Market cap (JPY 100mn)時価総額(億円)P/BP/EEV/EBITDA배당수익률Dividend yield配当利回りFCF 수익률FCF yieldFCF利回り순현금 ÷ 시총Net cash ÷ market capネットキャッシュ ÷ 時価総額투자유가증권 ÷ 시총Investment securities ÷ market cap投資有価証券 ÷ 時価総額
201722,0010.876.1 5.32.95%21.9% -82.4%—%
201816,8570.625.3 4.54.15%7.0% -108.7%—%
2019——-6.4 ——%—% —%—%
202016,1080.6914.1 6.44.38%26.1% -131.6%—%
202114,7180.512.7 3.74.80%-3.1% -181.5%—%
202214,0250.4910.0 7.44.73%-30.6% -231.7%—%
202321,8660.687.7 5.93.01%31.2% -114.0%—%
202421,0390.689.8 8.33.33%13.0% -87.0%—%
202537,9531.1314.7 7.02.41%9.6% -45.8%—%
시가총액 = 기말 주가(가공) × (발행주식 − 자기주식). EV = 시가총액 + 이자부채(리스 포함) − 현금·단기유가증권. 투자유가증권(정책보유 포함)은 EV 에서 빼지 않았다 — 표의 마지막 열이 그 크기다.Market cap = year-end price (derived) × (shares issued − treasury shares). EV = market cap + interest-bearing debt (including leases) − cash and short-term securities. Investment securities (including cross-shareholdings) are not deducted from EV — the last column of the table shows their size.時価総額 = 期末株価(加工値)×(発行済株式数 − 自己株式数)。EV = 時価総額 + 有利子負債(リースを含む)− 現金・短期有価証券。投資有価証券(政策保有株式を含む)はEVから差し引いていない — 表の最終列がその大きさだ。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 기말 주가는 그해 有報의 EPS × PER 로 역산한 가공값 — 시장 주가 원천을 쓰지 않았다. 적자 해는 PER 미기재로 빈칸.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Year-end share prices are derived values back-calculated as EPS × P/E from that year's annual securities report — no market price source is used. Loss years are blank because P/E is not reported.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 期末株価はその年の有報のEPS × PERから逆算した加工値 — 市場の株価データは使っていない。赤字の年はPER記載なしのため空欄。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑫ P/E 냐 P/B 냐 — 이 주가는 무엇을 따라가나P/E or P/B — what does this share price track?P/EかP/Bか — この株価は何に連動するか

有報 5년 표 FY2012~FY20255-year tables in the annual securities reports FY2012~FY2025有報の5年表 FY2012~FY2025 · Data as of 2026-03-31 · Created 2026-11-01
이 종목 · 그해 이익 기준This stock · same-year earningsこの銘柄 · その年の利益ベース
β 0.06
log(P/B) 를 log(ROE) 에 회귀한 기울기(±0.18, 11년). 1 이면 ROE 가 변해도 P/E 가 그대로(이익을 따라감), 0 이면 P/B 가 그대로(장부에 묶임). → P/B 에 묶여 있다.Slope from regressing log(P/B) on log(ROE) (±0.18, 11 years). 1 means P/E stays put as ROE changes (tracks earnings); 0 means P/B stays put (anchored to book). → anchored to P/B.log(P/B)をlog(ROE)に回帰した傾き(±0.18、11年)。1ならROEが変わってもP/Eは不変(利益に連動)、0ならP/Bが不変(簿価に縛られる)。→ P/Bに縛られている。
이 종목 · 3년 평균 이익 기준This stock · 3-year average earningsこの銘柄 · 3年平均利益ベース
β -0.11
일시 이익은 주가에 안 실린다(일회성이면 P/E 가 반대로 움직인다). 3년 평균 EPS 로 바꿔 다시 잰 값(±0.16, 8년) → 평탄화 이익으로 봐도 P/B 에 묶여 있다.One-off profits are not priced in (if a profit is one-off, P/E moves the other way). Re-measured with 3-year average EPS (±0.16, 8 years) → still anchored to P/B on smoothed earnings.一時的な利益は株価に織り込まれない(一過性ならP/Eが逆に動く)。3年平均EPSに替えて測り直した値(±0.16、8年) → 平準化利益で見てもP/Bに縛られている。
P/B 변화 분해 FY2012→FY2025Decomposition of P/B change FY2012→FY2025P/B変化の分解 FY2012→FY2025
+53%
log(P/B) 변화 = log(ROE) -7% + log(P/E) +59%. P/B 범위 0.49~1.13배 · 표준편차(log) P/E 0.48 vs P/B 0.24.Change in log(P/B) = log(ROE) -7% + log(P/E) +59%. P/B range 0.49~1.13x · standard deviation (log) P/E 0.48 vs P/B 0.24.log(P/B)の変化 = log(ROE) -7% + log(P/E) +59%。P/Bの範囲0.49~1.13倍 · 標準偏差(log)P/E 0.48 vs P/B 0.24。
일본 시장 표본 369사 · 회사 안 시계열Japan market sample, 369 companies · within-company time series日本市場の標本369社 · 企業内の時系列
β 0.15
같은 회귀를 369사(3443개 회사-연도)에 — 3년 평균 이익 기준 β 0.18. 회사별 β 중앙값 0.22. 그해 이익으로도, 3년 평균 이익으로도 β 가 0 쪽 — 일본 주가는 평균적으로 이익보다 장부(P/B)에 묶여 있다.The same regression across 369 companies (3443 company-years) — β on 3-year average earnings 0.18. Median company β 0.22. 그해 이익으로도, 3년 평균 이익으로도 β 가 0 쪽 — 일본 주가는 평균적으로 이익보다 장부(P/B)에 묶여 있다.同じ回帰を369社(3443の企業・年度)に — 3年平均利益ベースのβ 0.18。企業別βの中央値0.22。그해 이익으로도, 3년 평균 이익으로도 β 가 0 쪽 — 일본 주가는 평균적으로 이익보다 장부(P/B)에 묶여 있다.
점 하나 = 한 해(그해 ROE = EPS ÷ BPS, P/B = PER × EPS ÷ BPS — 둘 다 같은 有報 5년 표의 같은 주식 기준이라 분할·병합에 무관). 적자 해는 PER 이 비어 빠진다(3년).Each dot = one year (ROE that year = EPS ÷ BPS, P/B = P/E × EPS ÷ BPS — both on the same share basis from the same 5-year table in the annual securities report, so unaffected by splits and consolidations). Loss years have no P/E and are excluded (3 years).点1つ = 1年(その年のROE = EPS ÷ BPS、P/B = PER × EPS ÷ BPS — どちらも同じ有報5年表の同じ株式ベースのため、分割・併合の影響を受けない)。赤字の年はPERが空欄のため除外(3年)。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 한 회사의 연간 관측이라 표본이 작다(표준오차를 함께 적었다) · 적자 해는 빠진다 · 평탄화 이익은 그해 포함 직전 연도들의 EPS/BPS 평균.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Annual observations of a single company, so the sample is small (standard errors are shown alongside) · loss years are excluded · smoothed earnings are the average EPS/BPS of the preceding years including that year.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)のENEOSホールディングス株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 1社の年次観測のため標本が小さい(標準誤差を併記した)· 赤字の年は除外 · 平準化利益はその年を含む直近数年のEPS/BPSの平均。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑬ 측정 한계Measurement limitations測定の限界

1고정비·변동비는 계정 분류(매출원가 − 감가상각 = 변동, 판관비 + 감가상각 = 고정) 근사다. 매출원가 안 인건비(반고정)는 변동으로, 판관비 안 운임(변동)은 고정으로 들어간다. 감가상각은 현금흐름표 합계라 판관비 몫이 겹친다.고정비·변동비는 계정 분류(매출원가 − 감가상각 = 변동, 판관비 + 감가상각 = 고정) 근사다. 매출원가 안 인건비(반고정)는 변동으로, 판관비 안 운임(변동)은 고정으로 들어간다. 감가상각은 현금흐름표 합계라 판관비 몫이 겹친다.고정비·변동비는 계정 분류(매출원가 − 감가상각 = 변동, 판관비 + 감가상각 = 고정) 근사다. 매출원가 안 인건비(반고정)는 변동으로, 판관비 안 운임(변동)은 고정으로 들어간다. 감가상각은 현금흐름표 합계라 판관비 몫이 겹친다.
22024-04 四半期報告書 폐지 → 2024년 하반기부터는 반기만 있다. 4분기 편중·분기 회귀는 그 전 기간만.2024-04 四半期報告書 폐지 → 2024년 하반기부터는 반기만 있다. 4분기 편중·분기 회귀는 그 전 기간만.2024-04 四半期報告書 폐지 → 2024년 하반기부터는 반기만 있다. 4분기 편중·분기 회귀는 그 전 기간만.
3기말 주가는 有報 5년 표의 PER × EPS 로 역산한 가공값이다. 적자 해(PER 미기재)는 주가·P/B 가 비고, 그해는 P/E·P/B 판정에서 빠진다.기말 주가는 有報 5년 표의 PER × EPS 로 역산한 가공값이다. 적자 해(PER 미기재)는 주가·P/B 가 비고, 그해는 P/E·P/B 판정에서 빠진다.기말 주가는 有報 5년 표의 PER × EPS 로 역산한 가공값이다. 적자 해(PER 미기재)는 주가·P/B 가 비고, 그해는 P/E·P/B 판정에서 빠진다.
4ROIC 의 투하자본 = 자기자본 + 이자부채 − 현금·단기유가증권 − 투자유가증권(정책보유 포함). 세율은 그해 실효세율(0~60% 밖이면 30.6%).ROIC 의 투하자본 = 자기자본 + 이자부채 − 현금·단기유가증권 − 투자유가증권(정책보유 포함). 세율은 그해 실효세율(0~60% 밖이면 30.6%).ROIC 의 투하자본 = 자기자본 + 이자부채 − 현금·단기유가증권 − 투자유가증권(정책보유 포함). 세율은 그해 실효세율(0~60% 밖이면 30.6%).

같이 볼 페이지Related pages併せて見るページ